Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), has shown to be beneficial in the treatment of many types of metastatic cancers including metastatic colon cancer, renal cancer, non–small cell lung cancer (NSCLC), and breast cancer [1]–[5]. Here, VEGFA is linked to lung cancer.